Carmell Therapeutics has entered a definitive agreement and plan of merger with the regenerative medicine company Axolotl Biologix.
Axolotl’s shareholders will receive an initial equity value of $65m.
Go deeper with GlobalData
They will also potentially receive $75m in milestone equity payments linked to reaching revenue and business milestones.
Axolotl CEO Josh Sandberg stated: “I am excited to partner with Rajiv and Carmell to build on our shared vision of offering industry-leading products that positively impact patients’ lives. Our teams have worked very diligently, and this transaction creates unlimited possibilities.”
Axolotl focuses on designing, developing and selling human amnion-based allograft products for active soft tissue repair, aesthetics and orthopaedic applications.
The company is currently enrolling participants for a Phase I/II clinical trial aimed at treating ankle osteoarthritis.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt is also working on the development of a topical cosmeceutical product designed to rejuvenate the skin.
On 30 June 2023, Axolotl’s unaudited trailing 12-month (TTM) net revenue was $50m, with unaudited TTM earnings before interest, taxes, depreciation and amortisation from product sales reaching $5m.
Carmell executive chairman Rajiv Shukla stated: “I look forward to working with Josh and the Axolotl team to accelerate our goal of building Carmell into an industry-leading regenerative medicine company through a combination of in-house product development, bolt-on acquisitions and business development aimed at aesthetics/soft tissue and orthopaedic indications.”
